Oryzon Genomics S.A. (OTCMKTS:ORYZF) Stock In Focus After Latest News Update

December 14, 2021

Oryzon Genomics S.A. (OTCMKTS:ORYZF) was moving in a range after the clinical biopharmaceutical firm leveraging epigenetics to create treatments with unmet medical needs released positive efficacy findings from the current Phase IIa ALICE study. Latest News The trial evaluates a combination of iadademstat and azacitidine in unfit or elderly patients with acute myeloid leukemia. The company presented the data at the 63rd Annual American Society of Hematology Conference 2021. There…

Read More >>